Modality
Gene Therapy
MOA
KIF18Ai
Target
EGFR
Pathway
STING
FabryOvarian CaCLL
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
~Oct 2022
→ ~Jan 2024
Phase 2
Apr 2024
→ Apr 2025
Phase 2Current
NCT04972534
985 pts·Ovarian Ca
2024-04→2025-04·Terminated
985 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-0812mo agoPh3 Readout· Ovarian Ca
2026-01-123mo agoNDA· CLL
Trial Timeline
Q2Q3Q42025Q2Q3Q42026
P2/3
Termina…
Catalysts
Ph3 Readout
2025-04-08 · 12mo ago
Ovarian Ca
NDA
2026-01-12 · 3mo ago
CLL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04972534 | Phase 2/3 | Ovarian Ca | Terminated | 985 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Bemanaritide | Blueprint Medicines | Phase 2 | CD38 |